[Small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR)]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Activating mutations in the epidermal growth factor receptor (EGFR) gene are key drivers in certain lung cancers.
• Small molecule inhibitors targeting EGFR tyrosine kinase, such as gefitinib and erlotinib, have shown significant efficacy in patients with EGFR mutations.

Purpose of the Study:

• To review the clinical impact of EGFR mutations in lung cancer.
• To discuss the mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI).
• To highlight the development of strategies to overcome resistance and personalize lung cancer therapy.

Main Methods:

• Literature review of studies on EGFR mutations in lung cancer.
• Analysis of clinical trial data for EGFR-TKI efficacy and resistance patterns.
• Examination of molecular mechanisms underlying acquired resistance, including secondary EGFR mutations and MET gene amplification.

Main Results:

• EGFR mutations are predictive biomarkers for response to EGFR-TKIs in lung cancer.
• EGFR-TKIs prolong survival in patients with EGFR-mutated lung cancer.
• Acquired resistance to EGFR-TKIs is common, primarily mediated by secondary EGFR mutations and MET amplification.

Conclusions:

• Personalized lung cancer therapy based on genetic information, particularly EGFR mutation status, is a reality.
• Further research is needed to develop effective strategies to circumvent acquired resistance to EGFR-TKIs.
• Targeting EGFR and overcoming resistance mechanisms hold promise for improving long-term outcomes in lung cancer patients.